Drawing for DURESPA

USPTO serial 78233101

DURESPA

Reviewed by CopyMark Law Group

Status 601
Filing date
Status date
Registration date
—
Examiner
MAYS, PAULA
Law office
FILE REPOSITORY (FRANCONIA)

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with DURESPA?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Jane Ungaro

JANE UNGARO PFIZER INC201 TABOR RD LEGAL DIVISION 56/2MORRIS PLAINS NJ, 07950U.S. ARMY

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical preparations for the treatment of cardiovascular disease, central nervous system diseases and disorders, neurological disorders, urological disorders, urogenital disorders, gastrointestinal disorders, musculoskeletal disorders, allergies, diabetes, hypertension, erectile dysfunction, sexual dysfunction, stroke, cancer, migraines, pain, obesity, inflammation, inflammatory diseases, respiratory diseases, infectious diseases, immunological disorders, viral disorders, fungal disorders; pharmaceutical preparations, namely, cholesterol preparations, smoking cessation preparations, dermatological preparations, gynecological preparations, osteoporosis preparations, ophthalmological preparations, preparations for the treatment of HIV and AIDsACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Aug 28, 2003ABN1ABANDONMENT - EXPRESS MAILED—
Aug 28, 2003DOCKASSIGNED TO EXAMINER—
Aug 18, 2003MAILPAPER RECEIVED—

Frequently asked questions

Related guidance